Article
Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
Blood - 7 Mar 2024
O'Connor David, Valle-Inclán Jose Espejo, Conde Lucia, Bloye Gianna, Rahman Sunniyat, Costa Joana R, Bartram Jack, Adams Stuart, Wright Gary, Elrick Hillary, Wall Kerry, Dyer Sara, Howell Christopher, Jigoulina Galina, Herrero Javier, Cortes-Ciriano Isidro, Moorman Anthony V, Mansour Marc R
Abstract excerpt
ABSTRACT: T-ALL relapse usually occurs early but can occur much later, which has been suggested to represent a de novo leukemia. However, we conclusively demonstrate late relapse can evolve from a pre-leukemic subclone harbouring a non-coding mutation that evades initial chemotherapy.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.